Retina Associates, LLC: At the Forefront of Retinal Care
Our retina specialists advance and improve the treatment of diseases of the retina, macula, and vitreous through clinical studies, education, and the development of new instruments and techniques. Our physicians have participated in a multitude of retinal research studies and, in many, served as principal investigators or co-investigators. We proudly offer retinal clinical trials designed to enhance the vision, quality of life, and peace of mind of our patients.
Safely Advancing Quality of Care
Clinical trials involve scientific research into whether a new medication, device, or treatment strategy improves patient outcomes. Every treatment existing today has been through clinical trials. Not only do clinical trials help to develop new and improved treatment modalities, but they also connect patients with potentially vision-saving treatments before they’re available to the general public, which can make a huge difference for patients with severe or treatment-resistant cases.
You can be one of the first patients to benefit from a new medication or technique that goes on to be a respected and widely utilized standard of care. Furthermore, you can rest assured that our retina clinical trials adhere to the highest safety standards governed and reviewed by institutional review boards (IRBs).
Why Participate in a Retina-Related Clinical Trial?
Retina-related clinical trials allow participants to try new treatment methods that can slow the progression of eye-related diseases and improve vision outcomes. If your current treatment plan isn’t giving you optimal results, a retina clinical trial could offer a fresh new option.
Enroll in a Retina Associates Clinical Trial Today
Are you ready to be at the forefront of retina research and possibly improve your own vision and general well-being? Enroll in a clinical trial with the expert retina specialists at Retina Associates today. Review our upcoming studies below and contact us for more information.
Currently Enrolling
Sponsor: Ocular Therapeutix, Inc.
NCT07235085The purpose of the HELIOS-3 trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy (NPDR). OTX-TKI is an intravitreal hydrogel embedded with axitinib. When the OTX-TKI hydrogel is administered into the vitreous cavity of the eye, the hydrogel begins to slowly break down, which allows the axitinib to be slowly released over time.
Sponsor: AbbVie Inc. & REGENXBIO Inc.
NCT07592273The NAAVIGATE study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (SCS) for the treatment of diabetic retinopathy (DR) and prevention of vision-threatening events (VTEs) in participants with non-proliferative DR (NPDR) without center-involved diabetic macular edema (CI-DME).
Sponsor: AbbVie Inc.
NCT07007065The ACHIEVE study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy for the treatment of neovascular age-related macular degeneration (nAMD), also known as “wet” AMD. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with wet AMD.
Sponsor: Merck Sharp & Dohme LLC
NCT07705555Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
Sponsor: EyeBiotech Ltd.
NCT07496567TORRONTES is a study of an investigational drug called EYE201 (also called MK-8748), for the possible treatment of patients with decreased vision associated with Wet Age-related Macular Degeneration (wet AMD). EYE201 is designed to decrease fluid leaking and swelling in the retina by improving the health of retinal blood vessels
Sponsor: Regeneron Pharmaceuticals, Inc.
NCT06541704The SIENNA study is researching experimental drugs called pozelimab and cemdisiran in participants who have geographic atrophy (GA) caused by age-related macular degeneration (AMD). The aim of the study is to see how safe and effective cemdisiran alone and in combination with pozelimab are in slowing the progression of GA